Rosenberg M E, Hostetter T H
Department of Medicine, University of Minnesota, Minneapolis 55455.
Am J Kidney Dis. 1991 Oct;18(4):472-82. doi: 10.1016/s0272-6386(12)80116-8.
Control of hypertension improves the course of renal disease. We compared the renal hemodynamic and permselective responses to an angiotensin-converting enzyme inhibitor (CEI) (enalapril) and an alpha 1-antagonist (prazosin) in 14 patients with established glomerular disease. A single-blinded, randomized, cross-over design was used consisting of a 3-week baseline period followed by two 4-week treatment periods, which were separated by a 4-week washout period. During the treatment periods, the CEI or alpha 1-antagonist was added to the patients' baseline antihypertensive medications. Mean arterial pressure (MAP) was reduced to similar levels by both drugs, although the time-averaged blood pressure throughout the study was higher with the alpha 1-antagonist. Twenty-four-hour urinary protein, albumin, and IgG excretion were not significantly different at the end of the CEI and alpha 1-antagonist periods. However, compared with baseline values, significant decreases in total protein and IgG excretion occurred only during the CEI period, while albumin excretion decreased with both drugs. A 22% decrease in the fractional clearance of albumin (4.95 +/- 1.44 to 3.88 +/- 1.57 x 10(-3); P less than 0.01) and a 49% decrease in the fractional clearance of IgG (1.58 +/- 0.42 to 0.81 +/- 0.28 x 10(-3); P less than 0.001) occurred during CEI therapy with no significant changes in these parameters being seen with alpha 1-antagonist therapy (albumin: 4.95 +/- 1.44 to 4.48 +/- 1.51 x 10(-3), P = NS; IgG: 1.58 +/- 0.42 to 1.71 +/- 0.70 x 10(-3), P = NS). At the time of the fractional clearance measurements, MAP proved to be lower on the CEI. Reanalysis of the data for the subgroup of 11 patients without differences in MAP during the clearance period demonstrated a beneficial effect favoring CEI. Except for the greatest decreases in blood pressure (21 to 30 mm Hg), a greater antiproteinuric effect for a given decrease in blood pressure was seen with the CEI. Additionally, reduction in proteinuria occurred in a subset of seven patients whose baseline MAP was in the normotensive range. In conclusion, lowering MAP improves proteinuria. CEI appears to exert a more favourable effect even at similar MAP. Reductions in blood pressure, even within the accepted normal range, lessen permselective defects.
控制高血压可改善肾脏疾病的病程。我们比较了14例已确诊肾小球疾病患者对血管紧张素转换酶抑制剂(CEI)(依那普利)和α1拮抗剂(哌唑嗪)的肾脏血流动力学及选择性通透反应。采用单盲、随机、交叉设计,包括3周的基线期,随后是两个4周的治疗期,中间间隔4周的洗脱期。在治疗期,将CEI或α1拮抗剂添加到患者的基线抗高血压药物中。两种药物均将平均动脉压(MAP)降至相似水平,尽管在整个研究中α1拮抗剂的时间平均血压较高。在CEI和α1拮抗剂治疗期结束时,24小时尿蛋白、白蛋白和IgG排泄量无显著差异。然而,与基线值相比,仅在CEI治疗期总蛋白和IgG排泄量显著降低,而两种药物均使白蛋白排泄量降低。在CEI治疗期间,白蛋白分数清除率下降了22%(从4.95±1.44降至3.88±1.57×10⁻³;P<0.01),IgG分数清除率下降了49%(从1.58±0.42降至0.81±0.28×10⁻³;P<0.001),而α1拮抗剂治疗期间这些参数无显著变化(白蛋白:从4.95±1.44降至4.48±1.51×10⁻³,P=无显著性差异;IgG:从1.58±0.42降至1.71±0.70×10⁻³,P=无显著性差异)。在进行分数清除率测量时,CEI治疗时的MAP较低。对清除期MAP无差异的11例患者亚组的数据重新分析显示,CEI具有有益作用。除血压下降幅度最大(21至30mmHg)外,对于给定的血压下降,CEI具有更大的抗蛋白尿作用。此外,7例基线MAP在正常血压范围内的患者亚组出现了蛋白尿减少。总之,降低MAP可改善蛋白尿。即使在相似的MAP水平下,CEI似乎也能发挥更有利的作用。血压降低,即使在公认的正常范围内,也能减轻选择性通透缺陷。